immatics biotechnologies ...
0.03
-0.02 (-40.00%)
At close: Jan 14, 2025, 3:58 PM
0.05
60.00%
After-hours Jan 14, 2025, 07:49 PM EST
undefined%
Bid 0.04
Market Cap 460.48M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 0
PE Ratio (ttm) n/a
Forward PE n/a
Analyst n/a
Ask 0.06
Volume 51,484
Avg. Volume (20D) 0
Open 0.05
Previous Close 0.05
Day's Range 0.03 - 0.06
52-Week Range 0.03 - 0.06
Beta undefined

About IMTXW

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targ...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 2, 2020
Employees 542
Stock Exchange NASDAQ
Ticker Symbol IMTXW
No News article available yet